Regis Healthcare Limited (ASX:REG) shares were priced at $4.33 on 6 October 2026, down 0.69% on the day, and are down 32.56% over the past twelve months. The aged care operator released its FY26 financial results on 24 August 2026, covering the year ended 30 June 2026, with figures in Australian dollars.

Across the broader market, the S&P/ASX 200 Health Care index [XHJ] (INDEXASX: XHJ) stood at 31,982.20, up 0.63% (+200.50 points) as of 6 October, and is down 16% over the past year. Meanwhile, the S&P/ASX 200 stood at 8,735.70, up 0.57% (+49.30 points) at the same time, and is down 2.74% over the year.

Business Model and Operational Footprint

Regis is one of the largest aged care operators in Australia, founded over 30 years ago. It provides services to more than 10,000 older Australians through residential aged care homes, home care service hubs, day therapy and respite centres and retirement villages, supported by more than 13,000 nurses, carers and support professionals.

Revenue comes from government funding under the AN-ACC model, resident contributions such as hotelling and accommodation pricing, and refundable accommodation deposits (RADs), which fund the balance sheet. The company owns freehold homes and has a greenfield pipeline of about 1,300 beds across nine sites, including a 123-bed home at Toowong in Brisbane that is nearing completion for opening in summer 2026/27, with construction underway at Carlingford. Its acquisitions in FY26 added four homes with 600 beds in South-East Queensland (Rockpool) and two homes with 230 beds in Victoria (OC Health), while two homes in Far North Queensland were sold.

Sector Dynamics

The aged care sector is shaped by government funding settings. The new Aged Care Act commenced on 1 November 2025, with the government continuing to fund direct care costs through AN-ACC, the hotelling supplement becoming means-tested for new residents, and RAD retention of 2% a year, capped at five years, reintroduced for new residents. The maximum RAD room price without pricing authority approval rose from $550,000 to $750,000 on 1 January 2025 and reached $789,686 on 1 July 2026.

Labour costs are a further driver. Regis cited Fair Work Commission Work Value Case decisions, a 3.5% increase to minimum award wages from 1 July 2025, enterprise agreement pay rises and government-mandated care minute targets. AN-ACC price indexation effective 1 October 2025 was lower than expected and was described as insufficient to fully offset increases in staff and care delivery costs.

FY26 Results Update

Revenue from services was $1,350.6 million, up 16.3%, and underlying EBITDA was $138.0 million, up 9.7%. Underlying NPAT was $55.6 million, up 4.2%, and statutory NPAT was $55.7 million, up 13.8%. Staff expenses rose 18.7% to $1,055.1 million, or 78.1% of Revenue compared with 76.6%, and the underlying EBITDA Margin eased from 10.8% to 10.2%. Other income was $188.9 million, up 44.3%, including $153.5 million of imputed income on RADs. Net Operating Cash Flow was $336.3 million, up 9.8%, with net RAD cash inflow of $250.5 million, up 28.2%. Capital Expenditure rose 62.4% to $143.1 million, and net cash was $173.8 million, down 9.7% from $192.5 million. RAD Liability increased 24.8% to $2,279.1 million.

Mature home average occupancy was 96.0%, up from 95.6%, and occupied bed days rose 8% to 2.85 million. The Camberwell and Oxley homes reached 99% occupancy and generated net RAD inflow of $97.9 million. Staff turnover fell to 18% from 23%. The average incoming RAD rose 20% to $697,200. The sale of the Ayr and Home Hill homes produced a one-off pre-tax profit of $25.4 million, and one-off items in total were a net gain of $4.4 million before tax, including $13.7 million of Acquisition and integration costs. A final Dividend of 9.40 cents, fully franked, will be paid on 23 September 2026, taking total FY26 dividends to 18.40 cents, up 13%.

Growth Catalysts and Critical Operating Risks

Regis repriced about 70% of rooms in July and August 2026, lifting average advertised room prices by 10%. As new residents enter care, the progressive repricing of existing RADs is expected to generate more than $500 million of net operating cash inflow, and RAD retention Earnings are projected to exceed $50 million a year once fully phased in. The company has an active acquisition pipeline, a greenfield program of about 1,300 beds, and a goal of expanding beyond 10,000 beds. Investment in technology is intended to support clinical outcomes and productivity.

The release also identifies pressures. Staff costs grew faster than revenue, margins fell because indexation lagged cost increases, and the company continues to advocate for AN-ACC funding settings that reflect the cost of care. Capital expenditure and acquisitions absorbed $326.1 million of operating cash flow, net cash declined, and RAD liabilities grew. Funding rules under the new Aged Care Act, including means testing of the hotelling supplement, affect revenue for new residents. Acquisition and integration costs, employee entitlement adjustments and IT investment were among one-off charges of $13.7 million, $2.5 million and $4.3 million respectively.

The Bottom Line

Regis Healthcare reports higher revenue, EBITDA, NPAT, cash flow and dividends for FY26, alongside higher staff costs, a lower EBITDA margin, higher capital spending and lower net cash. Its shares are down 32.56% over the year. The company's own outlook references repricing, RAD retention under the new Aged Care Act, the Toowong opening and its development pipeline, while funding settings remain a stated area of advocacy.